Literature DB >> 1322670

A rheumatoid factor from a normal individual encoded by VH2 and V kappa II gene segments.

F Stüber1, S K Lee, S L Bridges, W J Koopman, H W Schroeder, F Gaskin, S M Fu.   

Abstract

OBJECTIVE: To gain insight into the immunoglobulin variable-region repertoire of anti-IgG antibodies (rheumatoid factors [RF]), we characterized the VH and V kappa gene segments utilized in an IgM-RF-secreting lymphoblastoid cell line (SSH23) isolated from a normal individual.
METHODS: The cell line SSH23 was established by Epstein-Barr virus transformation of peripheral blood non-T mononuclear cells. First-strand complementary DNA (cDNA) was generated and used for polymerase chain reaction amplification of the heavy and light chain variable domains. The amplified variable domains were sequenced and compared with an extensive database of germline and cDNA V gene segments.
RESULTS: The VH sequence was found to be identical to a previously described fetal VH2 incomplete cDNA and to differ by only 3 nucleotides from a JH proximal germline VH2 gene segment. To our knowledge, this is the first example of a VH2 rheumatoid factor. The V kappa 2-J kappa 4 light chain contains an uncommon 10-amino acid third complementarity-determining region (CDR 3).
CONCLUSION: Utilization of preimmune fetal VH gene segments and unusual light chain junctional diversity appear to be features shared by many physiologic and pathologic rheumatoid factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322670     DOI: 10.1002/art.1780350808

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  Rheumatoid factors in primary Sjögren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation.

Authors:  K E Elagib; M Børretzen; R Jonsson; H J Haga; J Thoen; K M Thompson; J B Natvig
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  Molecular structure of eight human autoreactive monoclonal antibodies.

Authors:  I Aguilera; J Melero; A Nuñez-Roldan; B Sanchez
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

3.  Clonally-related immunoglobulin VH domains and nonrandom use of DH gene segments in rheumatoid arthritis synovium.

Authors:  B E Clausen; S L Bridges; J C Lavelle; P G Fowler; S Gay; W J Koopman; H W Schroeder
Journal:  Mol Med       Date:  1998-04       Impact factor: 6.354

4.  Lupus-derived autoantibodies with dual autoactivity: anti-DNA and anti-Fc. II. Fine specificity of anti-self autoreactivity.

Authors:  C A Rumbley; E W Voss
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

5.  Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model.

Authors:  Wei-Zhong Ying; Christopher E Allen; Lisa M Curtis; Kristal J Aaron; Paul W Sanders
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

6.  Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein.

Authors:  W Z Ying; P W Sanders
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

7.  Rheumatoid factors from the peripheral blood of two patients with rheumatoid arthritis are genetically heterogeneous and somatically mutated.

Authors:  K Youngblood; L Fruchter; G Ding; J Lopez; V Bonagura; A Davidson
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

8.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

9.  A rheumatoid factor paradox: inhibition of rituximab effector function.

Authors:  Jonathan D Jones; Irene Shyu; Marianna M Newkirk; William F C Rigby
Journal:  Arthritis Res Ther       Date:  2013-01-25       Impact factor: 5.156

10.  Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VH gene segment usage and preferential usage of V lambda IIIb.

Authors:  Q Fang; C C Kannapell; F Gaskin; A Solomon; W J Koopman; S M Fu
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.